Focused On-demand Library for Dynein light chain 2, cytoplasmic

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96FJ2

UPID:

DYL2_HUMAN

Alternative names:

8 kDa dynein light chain b; Dynein light chain LC8-type 2

Alternative UPACC:

Q96FJ2; B2R5B4

Background:

Dynein light chain 2, cytoplasmic, also known as 8 kDa dynein light chain b or Dynein light chain LC8-type 2, plays a crucial role in the cytoplasmic dynein 1 complex. This protein is essential for the retrograde motility of vesicles and organelles along microtubules, facilitating the transport of cellular components. Its involvement in maintaining or altering the spatial distribution of cytoskeletal structures highlights its significance in cellular dynamics.

Therapeutic significance:

Understanding the role of Dynein light chain 2, cytoplasmic could open doors to potential therapeutic strategies. Its fundamental role in intracellular transport and cytoskeletal organization makes it a promising target for drug discovery, aiming to modulate cellular processes implicated in various diseases.